Novo Nordisk A/S (NYSE:NVO) is one of the Best Value Stocks to Buy for the Long Term. On March 2, Novo Nordisk A/S (NYSE:NVO) announced a €432 million (DKK 3.2 billion) investment in its Monksland facility in Athlone, Ireland, to boost production of oral GLP-1 treatments.
Management noted that this investment will allow the company to have a hub to serve international markets outside of the US. The investment is aimed at retrofitting the existing tableting plant, adding capacity for current and future GLP-1 drugs like oral Semaglutide. The company has already started construction on the 45-acre site and is expected to wrap up gradually from late 2027 to 2028.
Management also highlighted that the already recruited 260 employees at the site are expected to prioritize high-quality, sustainable oral treatments, while the construction is projected to create up to 500…



